Review
Unravelling Tumour Microenvironment in Melanoma at Single-Cell Level and Challenges to Checkpoint Immunotherapy

Xinyu Bai and Camelia Quek *

Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia
* Correspondence: camelia.quek@sydney.edu.au

Abstract: Melanoma is known as one of the most immunogenic tumours and is often characterised by high mutation burden, neoantigen load and immune infiltrate. The application of immunotherapies has led to impressive improvements in the clinical outcomes of advanced stage melanoma patients. The standard of care immunotherapies leverage the host immunological influence on tumour cells, which entail complex interactions among the tumour, stroma, and immune cells at the tumour microenvironmental level. However, not all cancer patients can achieve a long-term durable response to immunotherapy, and a significant proportion of patients develops resistance and still die from their disease. Owing to the multi-faceted problems of tumour and microenvironmental heterogeneity, identifying the key factors underlying tumour progression and immunotherapy resistance poses a great challenge. In this review, we outline the main challenges to current cancer immunotherapy research posed by tumour heterogeneity and microenvironment complexities including genomic and transcriptomic variability, selective outgrowth of tumour subpopulations, spatial and temporal tumour heterogeneity and the dynamic state of host immunity and microenvironment orchestration. We also highlight the opportunities to dissect tumour heterogeneity using single-cell sequencing and spatial platforms. Integrative analyses of large-scale datasets will enable in-depth exploration of biological questions, which facilitates the clinical application of translational research.

Keywords: melanoma; single-cell; transcriptomics; sequencing; spatial; immunotherapy; cancer; treatment; diagnosis

1. The Emergence of Single-Cell Sequencing and Spatial Platforms to Dissect Melanoma Microenvironment

In recent years, the emergence of single-cell sequencing and spatially resolved multi-omics platforms have rapidly advanced the field of immuno-oncology research. These technologies brought higher resolution to characterise the cellular composition and transcriptional programs within the tumour microenvironment (TME), offering new opportunities to uncover rare cell types, infer cellular interactions and identify molecular targets, hence offering better understandings of the mechanisms of immunotherapy response and resistance. In this section, we provide a brief overview of single-cell platforms that are widely used in cancer immunotherapy research.

1.1. Single-Cell Sequencing

Single-cell sequencing platforms are subdivided into cell-dissociated (individual cells are sorted prior to sequencing) and spatially resolved methods (map the location of the transcripts in an intact tissue section). Technologies that sequence the dissociated cells are broadly classified by their respective cell isolation methods. Droplet encapsulation methods, including 10x Genomics Chromium and Dolomite-Bio Nadia, are popular platforms for the sequencing of tumour dissociate samples due to the high number of sorted cells, allowing for high-throughput and relatively higher cost-effectiveness [1,2]. Microwell
encapsulation platforms such as Fluidigm C1, Illumina/Bio-Rad ddSeq, Takara-Bio ICell8 and BD Rhapsody are commonly available platforms that have been developed over time. These platforms can vary in cost, labour, and sample size, and would thus be selective for different studies in cancer research. Since tumour samples often require the platform to accommodate for a range of cell size due to the multitude of cell types within the TME, more recent platforms such as the Rapsody and Illumina/Bio-Rad are more popular in this field [3]. Lastly, traditional fluorescence-activated cell sorting (FACS) based single-cell sequencing approaches such as SMART-seq2 [4] and MARS-seq [5] are well-established techniques in the laboratory. FACS is unrestricted by the size and morphology of the cells and total cell numbers, facilitating the selection of rare cell types from tumour samples. However, FACS entails staining the cell dissociate with pre-selected antibodies, and thus the identification of cell subtypes requires marker multiplexing for accurate cell sorting and downstream analysis [3].

1.2. Spatially Resolved Genomics and Transcriptomics

The TME is a heterogeneous tissue architecture containing not only the tumour cells, but also a variety of non-immune and immune cells within the microenvironment. Each cell is constantly communicating with other cells and this in turn influences the function and fate of the cell. Furthermore, intracellular organisations of DNA and RNA can provide critical clues to the gene expression and post-transcriptional regulation underlying drug resistance. Thus, the spatial organisation of cells is critical for the accurate interpretation of tissue functions and cellular interactions. Single-cell spatial omics technologies have been developed to preserve the tissue context which retain the cell location information that helps to provide further insights into the interplay between tumour and the microenvironmental cells.

Two classes of methods have been popularised for imaging-based single-cell genomics and transcriptomics, based on multiplexed fluorescence in situ hybridisation (FISH) or in situ sequencing. FISH has been well-established for the visualisation and quantification of RNA at the single-molecule level [6,7], and multiplexed FISH, using combinatorial fluorescent colours, is developed for the gene-expression profiling of single-cells [8]. But the limited number of distinct colour channels posed a challenge to expanding the number of detectable targets for genome-scale imaging. Until this date, multiplexed error-robust (FISH) MERFISH has been used, which implements combinatorial labelling detected by sequential imaging and error robust binary coding schemes [9]. MERFISH has since been extended to DNA imaging, which enables simultaneous imaging of the 3D organisation of the chromatin at the genome scale [10]. Another multiplexed FISH method known as seqFISH+ uses sequential colour codes to detect RNAs and a binary code error-correction scheme akin to MERFISH. Both MERFISH and seqFISH+ have reported the imaging of transcripts for 10,000 genes in single cells [11,12]. Overall, multiplexed FISH approaches provide in situ single-cell transcriptomics and 3D genome analyses with high spatial resolution.

Imaging-based in situ sequencing approaches for single cell transcriptomic analysis are developed in parallel, and can be performed in either a targeted or untargeted manner for hypothesis-testing or empirical studies in cancer research. For targeted in situ sequencing, Ke et al. first described a method based on padlock probing, rolling-circle amplification and sequencing-by-ligation chemistry that can be applied to fixed cells and tissues [13]. More recent adaptations have used a multitude of methods to improve the multiplexity or detection efficiency of in situ sequencing, such as eliminating the inefficient RNA-to-cDNA conversion step, improving sequencing accuracy, using hydrogel-based clearing or sample expansion, combining with FISH, or using more efficient gap-filling enzymes [14–17]. An example is STARmap which integrates hydrogel-tissue chemistry, targeted signal amplification and sequencing method to achieve simultaneous imaging of up to 1020 targeted genes with a detection efficiency comparable to that of single-cell RNA sequencing [14]. In untargeted in situ sequencing, FISSEQ, can achieve genome-wide coverage and the detection of >8000 genes in the same sample [14].
Spatial transcriptomic analysis can also be achieved by spatially resolved RNA capture followed by sequencing. This was first demonstrated by Ståhl et al., where spatially barcoded and oligo(dT) probes are printed as microarrays of spots on the surface of glass slides [18]. After placing the tissue sections on the array, enzymic permeabilisation releases the mRNA from the tissue, which becomes free to hybridise with surface probes. Initial microarrays consisted of spots of ~100 µm in diameter, which captured a mix of tens of cells for transcriptomic profiling. This spatial transcriptomic technology was further developed and commercialised as 10x Genomics Visium, which increased the sensitivity and throughput by reducing the spot diameter to 55 µm. Depending on tissue type and thickness, the resolution was improved to offer an average gene expression profile of 1–10 cells in a single spot. To enable single cell resolution, Slide-seq [19] and HDST [20] are developed to capture cellular and biological expression at a single-cell level. Slide-seq operates on a monolayer of 10-µm beads, with each bead decoded by SOLiD [21] sequencing chemistry, to identify its spatial location. In HDST, the spatial resolution was improved to subcellular levels by packing 2-µm beads together, with a sequential hybridisation strategy to decode the spatial barcodes [20]. As sequencing technology advances, multimodal spatial profiling is becoming possible. The introduction of new in situ barcoding schemes for more biomolecules will yield more layers of molecular information from the same tissue. Combinations of barcoding strategies will enable spatial multi-omics approaches to retrieve information about splice variants, non-coding RNA, genetic and epigenetic alterations and proteins, all in a single experiment [22]. Some of these layers are already being added to the transcriptomic profiling of tissues, such as SM (Spatial Multi-omics)-Oomics [23] and DBIT-seq [24], which offer parallel spatial transcriptomic profiling and antibody-based protein barcoding.

Integrated analyses of single-cell sequencing and spatial multi-omics are revealing TME details of cellular and subcellular organisation at an unprecedented level. Applications of these technologies have demonstrated exciting results, such as the generation of highly granular and functionally annotated spatial cell atlases [25], identification of potential ligand-receptor and paracrine signalling [26], and the provision of insights into tumour and immune cell evolution [27]. Future expansion of these technologies offers promising opportunities to study tumour heterogeneity. Novel signalling pathways unravelled by non-targeted sequencing can be screened for new therapeutic targets. Interaction events identified by ligand-receptor analyses will be stratified by pairs of spatially colocalised cells, thereby providing a more accurate view of routes of communication that will, for instance, facilitate the differentiation of effector and bystander cells in the TME. Trajectory analysis algorithms can also take advantage of the spatial positions of cells in associated transitional stages with cell-cell interaction events or spatial niches within the tissue environment.

2. Insights into Heterogeneity of Tumour Microenvironment from Single-Cell Expression Profiling

2.1. Inter- and Intra-Tumoural Heterogeneity

Tumour heterogeneity is a major driver of cancer progression, treatment resistance, and recurrences [28,29]. The heterogeneity of tumours and TME is broadly categorised into inter-tumour heterogeneity and intra-tumour heterogeneity [30–32].

Inter-tumoural heterogeneity (also known as inter-lesion heterogeneity) refers to the variations of different tumour genotypes among patients, even within the same histological subtypes [32,33]. Upon evaluating the single-cell transcriptional program from 19 metastatic melanoma tumours, Tirosh et al. identified a rare therapy-resistant subpopulation of melanoma cells expressing high levels of AXL Receptor Tyrosine Kinase inside the heterogenous tumours harbouring MITF (microphthalmia-associated transcription factor) due to clonal selection after targeted treatment with RAF/MEK inhibition [34]. MITF is an established contributor of melanoma heterogeneity through its multi-pathway influence on melanocyte differentiation, proliferation, and metastatic potential. In particular, low MITF in melanoma was shown to induce phenotype switching as an invasive mechanism [35].
and thus the changing expression of this transcription factor can lead to the subsequent generation of resistant melanoma subpopulations [36,37]. In another cohort of patients with triple negative breast cancer, Wu et al. observed that the non-immune cell population, including cancer-associated fibroblasts in the complex stromal compartment, was functioning as an immune checkpoint for molecule expression, and its close interactions with T lymphocytes through lymphocyte activation and complement pathways were vital in regulating anti-tumour immunity [25].

Intra-tumoural heterogeneity (also known as intra-lesion heterogeneity) refers to the presence of distinct subpopulations of cancer cells with unique genetic traits in the single tumour of a patient, which can exhibit across different spatial locations of a tumour or evolve over time [32,38]. By inferring the genomic and transcriptional state changes of the TME and non-neoplastic cells among primary and metastatic tumours in patients with uveal melanoma (UM), Durante et al. found that class 1 UM subclones with low metastatic rate and signature driver mutations (EIF1AX and SF3B1) continue to evolve with the development of canonical/non-canonical aberrations that contribute to tumour progression [27]. Class 2 UM subclones with BAP1 inactivating mutations create an immunosuppressive microenvironment that facilitates metastasis through immune evasion [27]. Intra-tumoural heterogeneity was also observed in the transcriptomes of single cells from matched primary tumours and lymph node metastases in head and neck squamous cell carcinoma (HNSCC) patients. Puram et al. identified that tumour cells varied within patients in their expression of signatures strongly related to partial epithelial-to-mesenchymal transition (p-EMT), promoting resistance to anti-tumour immunity through dampening T lymphocyte-specific cytokines or regulating the expression of multiple inhibitory immune checkpoint molecules [39]. Such underlying heterogeneity provides deeper insights into one of the major causes of patients who either fail to respond to immunotherapy initially, or experience relapse after treatment.

2.2. The Spectrum of Spatial and Temporal Intra-Tumoural Heterogeneity

Heterogeneity in the tumour is not only limited to cancer cells, but also influences peritumoural stroma cells, tumour-infiltrating lymphocytes, and other stimulatory/inhibitory elements [33,40]. This heterogeneity includes spatial heterogeneity, which describes the non-uniform distribution of genetically diverse clonal populations across different disease sites or within a single site or tumour, and temporal heterogeneity, a term applied to polyclonal features of an individual tumour that evolve over time (i.e., heterogeneity between the primary tumour and a subsequent local or distant recurrence within a patient) [28,41,42].

Spatial heterogeneity is often defined as the differences in features such as genomics and cell morphology within an individual primary or metastatic tumour (intra-tumoural), and between different tumours within the same individual (intra-patient). In a retrospective cohort study, Jerby-Aron et al. revealed a resistance programme associated with T cell exclusion and cyclin-dependent kinases (CDK4 and CDK6) using single-cell RNA sequencing from 33 melanoma patients, and further validated on 90 samples from 26 patients with multiple biopsies per patient [43]. The inter-patient differences in the therapy-resistant expression programs were larger than intra-patient, implying the intrinsic differences that reflect different treatment responses and outcomes [43]. In addition, a prospective cohort study of 327 tumour regions from 100 cases of early stage non-small-cell lung cancer highlighted that more than 75% of driver mutations in somatic cells were broadly heterogeneous and were inconsistent in all samples when metastases were detected in patients with the same tumour [44]. The extent of spatial heterogeneity of molecular and cellular features within an individual tumour affects the utility of bulk gene expression signatures as markers associated with poor prognosis or therapy-resistant biomarkers.

Temporal heterogeneity refers to the initial (primary) tumour cells that have evolved with different mutational processes and selective pressures, resulting in variations of molecular composition of the tumours. The tumour cells also affect the intravascular cells, immune cells, stroma cells, and other cell types that constitute the complex TME [29,45]. The
tumour immune compartment, along with the clonal selection of tumour cells, can influence response to anti-tumour treatments [29]. Analysis of single-cell transcriptomic profiles of 32 melanoma patients before and after checkpoint-based treatment indicated that the transitions between exhausted and memory effector T cell states were reflective of tumour regression, and the presence of CD8+ T cells with a specific transcription factor, TCF7, was identified as a predictive marker of response for immunotherapy [46]. Furthermore, the tracking of T cell clones and their transcriptional phenotypes from patients with basal or squamous cell carcinoma before and after anti-PD-1 therapy, highlighted the fact that the clonal expansion of neoantigen-specific T cells from the peripheral compartment were associated with responses to immunotherapy [47].

3. Clinical Considerations of Tumour Microenvironment Heterogeneity in Response and Resistance to Checkpoint-Based Immunotherapies

3.1. Impact of Tumour and Immune Microenvironment Heterogeneity on Response to Immunotherapies

In recent years, a plethora of evidence has demonstrated that the genetic and immunological heterogeneity in the TME influences the likelihood of malignant cells surviving immunotherapies in patients with solid tumours, including melanoma [3,33,40,43,46]. Achieving objective responses to immune checkpoint therapies can vary, based on the neoantigen and immunological profiles of the TME [48]. For instance, patients with high intra-tumoural heterogeneity of neoantigens that responded to T cell-antitumoural immunity had decreased fractions of clonal immunogenic neoantigens and generally responded less to T cells during immune checkpoint therapies [49]. Experimental mouse model studies also demonstrated that a homogenous population of immunogenic neoantigens was critical to the success of responsiveness to immunotherapies [38,50,51]. In the CA209-038 study of 68 patients with advanced melanoma who progressed on ipilimumab before and after nivolumab treatment, cytolytic activity was increased during treatment and represented the immune-inflamed environment (a high level of T cell infiltration) that enriched pretreated tumours of anti-PD-1 responders [52]. However, in another cohort of the study, tumours with high cytolytic activity and interferon-γ scores failed to associate with clinical responses to anti-PD-1 therapy [40]. Jerby-Arnon et al. raised the difficulty of using bulk genomic and transcriptomic data to recover intracellular programmes of malignant cells, resulting in the discrepancy of linking malignant cell states to high (immune-inflamed tumour) or low (non-inflamed tumour) levels of tumour-infiltrating T cells [43]. The integrative single-cell strategy has enabled Jerby-Arnon et al. to define an immune-exclusion gene expression programs, including a cyclin-dependent kinase pathway to differentiate immune-inflamed from non-inflamed tumours [43]. Dissecting heterogeneity in the TME at single cell resolution will be necessary to fully understand tumour behaviour and its response to treatment.

3.2. Heterogenous Responses in Patients with Innate and Acquired Resistance

The patterns of treatment response heterogeneity are becoming more relevant from a clinical point of view, especially for patients who relapse after treatment and develop disease progression or recurrence [53,54]. Drugs that target a single biological pathway may induce the emergence of new mutation(s) in the tumour cells, favouring alternative pathways and further tumour progression [55,56]. These drugs can cause changes in the molecular composition of the tumour cells, leading to the dominance of therapy-resistant clones [57]. Non-responding patients with drug-resistant subpopulations of cells within the tumours can be categorised into two main groups: (i) primary or innate resistance refers to those who fail to respond to immunotherapies or have stable disease for less than 6 months before disease progression, and (ii) secondary or acquired resistance refers to those who relapse after an initial response to immunotherapies and develop disease progression [58–60]. Using a targeted single-cell approach, Kakavand et al. observed that the respective 28% and 22% of metastatic melanoma patients with acquired resistance to anti-PD-1 based therapies developed tumoural PTEN loss and impaired HLA-A regulation in the TME,
implying tumours across patients achieved resistance in different ways [61]. Most of the current research on tumour heterogeneity of treatment responses has come from targeted drug therapies. In an early landmark study conducted by Tirosh et al. using Smart-seq2 protocol to dissect a heterogenous mixture of malignant cells expressing different levels of AXL kinase, it was identified that AXL-high cells were resistant in tumours treated with vemurafenib (BRAFi) or dabrafenib (BRAFi) and trametinib (RAF/MEKi), a mechanism that infers the use of checkpoint-based immunotherapies for patients who fail conventional targeted therapies [34]. Furthermore, since a low MITF/AXL ratio was recognised as a predictor of early resistance [36], microRNA (miRNA) regulation of MITF expression was also explored as a novel therapeutic target to reverse the resistant phenotype [62–64] among many other miRNA pathways dysregulated in melanoma [65]. MITF expression regulates melanogenesis via the active transcription of pigmentation genes, including DCT, which encodes for dopachrome tautomerase [66]. Ho et al. identified the upregulation of DCT in rare drug-resistant subpopulations of human melanoma cells, prior to BRAFi treatment, which was only present in the single-cell RNA analysis when compared to bulk RNA sequencing [67]. Another mechanism of resistance to targeted therapies in melanoma involves the intrinsic control of apoptotic pathway mediated by the overexpression of pro-survival members of the BCL-2 family, shown in cell culture studies [68,69]. Selective inhibition of these BCL-2 family proteins is being explored in potential combinatory targeted therapy drugs, and is further reviewed elsewhere [70]. Overall, the genetic and non-genetic features of heterogeneity present at baseline and acquired post-treatment must be considered in clinical decision making, and similar single-cell investigations should be performed on longitudinal patient samples undergoing immunotherapy to reveal new mechanisms of resistance.

4. Heterogenous Expression of PD-L1 in the Tumour-Immune Microenvironment

PD-L1 expression level is identified in either tumour or immune cells and is often a selection criterion for predicting clinical response to PD-1 or PD-L1 inhibitors across various solid tumour types, including melanoma [71,72]. Although PD-L1 diagnostic testing is now established as a routine clinical practice, the expression level of PD-L1 is heterogenous both within and among tumour sites on various spatial and temporal scales [73,74]. A plethora of studies, including the CheckMate 067 trial, highlight the fact that the level of PD-L1 expression alone is a poor predictive biomarker, for which approximately 20% of patients whose tumours have minimal or no PD-L1 expression may achieve an objective response to anti-PD-1/PD-L1 treatment [71,73–76]. Upon evaluating pre-treatment biopsies from melanoma patients treated with anti-PD-1 therapy in a phase I clinical trial, Shin et al. observed that the upregulation of surface PD-L1 expression through the interferon-γ receptor pathway was heterogenous in subclones harbouring defective Janus kinases JAK1 and JAK2 [77]. In addition, the discrepancy in PD-L1 expression was also identified in subclones within the tumour immune microenvironment harboring impaired antigen processing and presentation machinery in patients receiving immunotherapies, and has been associated with poor clinical outcomes in melanoma and other cancer types such as lung cancer and colorectal carcinoma [78–80]. It is likely that the emerging heterogeneity of PD-L1 expression may explain why a subset of patients with tumours expressing PD-L1+ fail to respond, while some with PD-L1– negative neoplasms respond well to checkpoint-based immunotherapies.

5. Integrating Tumour Microenvironment Heterogeneity into Clinical Decision Making

The rapid advancements in single-cell sequencing and spatial technologies have shed light on modern cancer research, while the improved understanding of patient and tumour microenvironmental heterogeneity has brought new challenges to optimising therapeutic strategies. The field is moving towards translational applications of biological discoveries and has great potential in guiding clinical decision making.
As reviewed in the earlier sections, inter- and intra-tumoural heterogeneity encompasses a multitude of factors that define the unique biology of a tumour or tumour clone. These unique factors are driven by a combination of intrinsic and extrinsic changes which can be detected as variability at a multi-omics level. These changes can be leveraged using next-generation sequencing to reveal therapeutic vulnerabilities of cancer patients. This was demonstrated by the development of highly selective BRAF inhibitors (vemurafenib and dabrafenib) for melanoma patients after the identification of the target mutation [81,82]. Although the development of targeted therapies has transformed the treatment landscape for advanced melanoma, acquired resistance still poses a great challenge to improving patient outcome [59]. Over the years, several published works have identified the activation of compensatory pathways, which has led to the development of combinatory therapies such as dual BRAF/MEK inhibition [83,84]. However, the heterogeneity of resistance mechanisms presents a challenge in creating a rationally designed combination strategy that will be applicable for all patients. Previous studies have identified many more overlapping pathways with defined mechanisms of resistance, including NRAS, PI3K, PDGFR, IGF-1R, and GFR, among others [85,86]. A study analysing 132 melanoma samples that progressed with BRAF inhibitor treatment reported that a defined resistance mechanism was only identified in 58% of samples [85]. Further work using non-targeted sequencing methods is required to decipher novel mechanisms of therapy resistance and guide the development of therapeutic strategies.

In relation to discovering the features of TME heterogeneity and mechanisms of resistance, combinatory and personalised checkpoint immunotherapy strategies for melanoma are being actively researched. The CheckMate 067 trial demonstrated the superior efficacy of combination nivolumab plus ipilimumab over nivolumab or ipilimumab alone, though with increases in the rates of immune-related adverse events [87]. Clinical trials for other cancers have also validated the combination of immunotherapy and other therapeutic agents with independent anti-tumour effects, showing prolonged overall and progression-free survival in patients treated with combinatory regimens [88,89]. To overcome adaptive immunotherapy resistance in the TME, targeting other checkpoints including lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and ITIM domain (TIGIT), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), V-domain immunoglobulin suppressor of T cell activation (VISTA), B7 homolog 3 protein (B7-H3), inducible T cell costimulator (ICOS), and B and T lymphocyte attenuator (BTLA) are currently being tested in multiple clinical trials [90], with those involving solid tumours summarised in Table 1. With the expansion of translational research and the validation of novel drug targets in clinical trials, alternative checkpoint inhibitors are becoming feasible and promising options for personalising immunotherapy for solid tumours.

The complex and dynamic signalling network within the TME can also provide insight into the degree of interactive heterogeneity seen in tumours. Inhibition of the RAS/RAF/MAPK pathway not only results in the upregulation of compensatory receptor tyrosine kinase pathways [91], but has also been shown to modulate the host immune response, including alterations in T-cell responses and the expression of PD-L1 [92,93]. A separate study reported that the loss of tumour suppressor PTEN was associated with T cell exclusion and an immunosuppressed TME [94]. These findings identified genetic changes with cellular and phenotypic features that facilitated crosstalk between the intrinsic and extrinsic factors in the modulation of TME heterogeneity. This also sparked interest in combining targeted agents and immunotherapy to offer both short- and long-term benefits to cancer patients, which led to multiple clinical trials where molecular testing strategies are employed for both patient stratification and biomarker discovery purposes [95,96].
| Target Drug   | Clinical Trial ID | Phase | Settings | Tumour Types | Treatment Arms | Status          |
|---------------|-------------------|-------|----------|--------------|----------------|-----------------|
| LAG-3 Eftilagimod α (IMP321) | NCT03252938 | 1     | Advanced/metastatic | Solid tumours | Eftilagimod α | Recruiting      |
|               | NCT00324623 | 1     | Advanced/metastatic | Melanoma      | Cyclophosphamide, fludarabine followed by melan-A VLP vaccine and eftilagimod α | Completed       |
|               | NCT00365937 | 1     | Adjuvant         | Melanoma      | Eftilagimod α ± HLA-A2 peptides | Terminated      |
|               | NCT01308294 | 1, 2  | Stage II-IV     | Melanoma      | Eftilagimod α + tumour antigenic peptides + monatide | Terminated      |
| Relatlimab (BMS-986016) | NCT02966548 | 1     | Advanced/metastatic | Solid tumours | Relatlimab ± nivolumab | Active, not recruiting |
|               | NCT01968109 | 1     | First. second line | Solid tumours | Relatlimab ± nivolumab | Active, not recruiting |
|               | NCT03743766 | 2     | Advanced/metastatic | Melanoma      | Relatlimab + nivolumab | Recruiting      |
|               | NCT03470922 | 2, 3  | Advanced/metastaticC | Melanoma      | Relatlimab ± nivolumab | Active, not recruiting |
|               | NCT03335540 | 1, 2  | Advanced/metastatic | Solid tumours | Relatlimab + nivolumab or cabiralizumab or ipilimumab or IDO1 inhibitor or radiation therapy | Active, not recruiting |
|               | NCT02519322 | 2     | Neoadjuvant and adjuvant | Melanoma      | Nivolumab ± relatlimab or ipilimumab | Recruiting      |
|               | NCT03459222 | 2     | Advanced/metastatic | Solid tumours | Relatlimab + nivolumab or relatlimab + nivolumab + ipilimumab | Recruiting      |
| LAG525 | NCT02460224 | 1, 2  | Advanced/metastatic | Solid tumours | LAG525 ± spartalizumab (anti-PD-1) | Completed      |
|               | NCT03365791 | 2     | Advanced/metastatic | Solid or hematologic malignancy | LAG525 + spartalizumab (anti-PD-1) | Completed      |
| Fianlimab (REGN3767) | NCT03005782 | 1     | Advanced/metastatic | Solid tumours or lymphomas | Fianlimab ± cemiplimab (anti-PD-1) | Active, not recruiting |
| BI 754111 | NCT03433898 | 1     | Advanced/metastatic | Solid tumours | BI 754111 ± BI 754091 (anti-PD-1) | Active, not recruiting |
|               | NCT03156114 | 1     | Advanced/metastatic | Solid tumours | BI 754111 ± BI 754091 (anti-PD-1) | Active, not recruiting |
|               | NCT03697304 | 2     | Advanced/metastatic | Solid tumours | BI 754111 or BI 836880 (bispecific VEGF and Ang2 Ab) + BI 754091 (anti-PD-1) | Active, not recruiting |
|               | NCT03964233 | 1     | Advanced/metastatic | Solid tumours | BI 754111 + BI 754091 ± BI 907828 (MDM2-p53 antagonist) | Recruiting      |
| Sym022 | NCT03489369 | 1     | Advanced/metastatic | Solid tumours or lymphomas | Sym022 | Completed      |
|               | NCT03311412 | 1     | Advanced/metastatic | Solid tumours or lymphomas | Sym022 + Sym021 (anti-PD-1) ± Sym023 (anti-TIM-3) | Completed      |
| MGD013 | NCT03219268 | 1     | Advanced/metastatic | Solid or hematologic malignancy | MGD013 + margetuximab (anti-HER2 monoclonal antibody) | Active, not recruiting |
| Target         | Drug                              | Clinical Trial ID | Phase | Settings                          | Tumour Types            | Treatment Arms                                                                                     | Status               |
|----------------|-----------------------------------|-------------------|-------|-----------------------------------|-------------------------|----------------------------------------------------------------------------------------------------|----------------------|
| TSR-033        | NCT03250832                       | 1                 | Advanced/metastatic | Solid tumours                  | TSR-033 ± dostarlimab ± mFOLFOX6 or FOLFIRI ± bevacizumab | Active, not recruiting                                    |
| INCAGN02385    | NCT03538028                       | 1                 | Advanced/metastatic | Solid tumours                  | INCAGN02385             | Completed                                                                                           |
|                | NCT04370704                       | 1, 2              | Advanced/metastatic | Solid tumours                  | INCAGN02385 + INCAGN02390 (Anti-TIM-3) ± INCMG00012 (anti-PD-1) | Recruiting                                                      |
| XmAb22841      | NCT03849469                       | 1                 | Advanced/metastatic | Solid tumours                  | XmAb22841 ± pembrolizumab | Active, not recruiting                                    |
| LBL-007        | NCT04640545                       | 1                 | Advanced/metastatic | Melanoma                       | LBL-007 + toriparimab (anti-PD-1) | Recruiting                                                      |
|                | FS118                             | 1                 | Advanced/metastatic | Solid or hematologic malignancy | FS118                   | Recruiting                                                                                           |
| RO7247669      | NCT04140500                       | 1                 | Advanced/metastatic | Solid tumours                  | RO7247669               | Recruiting                                                                                           |
| EMB-02         | NCT04618393                       | 1, 2              | Advanced/metastatic | Solid tumours                  | EMB-02                  | Recruiting                                                                                           |
| Tiragolumab (MTIG7192A/RG-6058) | NCT02794571                   | 1                 | Locally advanced or metastatic | Solid tumours                  | Tiragolumab ± atezolizumab ± chemotherapy | Recruiting                                                      |
| Vibostolimab (MK-7684) | NCT02964013                  | 1                 | Advanced/metastatic | Solid tumours                  | Vibostolimab ± pembrolizumab ± pemetrexed/carboplatin: carboplatin + cisplatin + etoposide | Active, not recruiting                                    |
|                | NCT04305054                       | 1, 2              | First line         | Melanoma                       | Pembrolizumab ± quavonilimab (MK-1308) ± lenvatinib | Recruiting                                                      |
|                | NCT04305041                       | 1, 2              | Stage IV           | Melanoma                       | Pembrolizumab ± quavonilimab + vibostolimab or lenvatinib | Recruiting                                                      |
|                | NCT04303169                       | 1, 2              | Stage III          | Melanoma                       | Pembrolizumab ± vibostolimab or V937 (oncolytic virus) | Recruiting                                                      |
| OMP-313M32     | NCT03119428                       | 1                 | Locally advanced or metastatic | Solid tumours                  | OMP-313M32 ± nivolumab | Terminated                                                                                           |
| BMS-986207     | NCT02913313                       | 1, 2              | Advanced/metastatic | Solid tumours                  | BMS-986207 ± nivolumab ± ipilimumab | Recruiting                                                      |
|                | NCT04570839                       | 1, 2              | Advanced/metastatic | Solid tumours                  | BMS-986207 + nivolumab + COM701 (anti-PVRIG Ab) | Recruiting                                                      |
| Domvaniomilum (AB-154) | NCT03628677                  | 1                 | Advanced/metastatic | Solid tumours                  | Domvaniomilum + zimbereilimab (AB122, anti-PD-1) | Active, not recruiting                                    |
| ASP8374        | NCT03945253                       | 1                 | Advanced/metastatic | Solid tumours                  | ASP8374                | Completed                                                                                           |
|                | NCT03260322                       | 1                 | Advanced/metastatic | Solid tumours                  | ASP8374 ± pembrolizumab | Completed                                                                                           |
| IBI939         | NCT04353830                       | 1                 | Advanced/metastatic | Solid tumours                  | IBI939 ± sintilimab (anti-PD-1) | Recruiting                                                      |
| Ociperlimab (BGB-A1217) | NCT04047862                  | 1                 | Advanced/metastatic | Solid tumours                  | Ociperlimab + tislelimab (anti-PD-1) ± chemotherapy | Recruiting                                                      |
| COM902         | NCT04354246                       | 1                 | Advanced/metastatic | Solid tumours                  | COM902 ± COM701 (anti-PVRIG Ab) | Recruiting                                                      |
| Target | Drug | Clinical Trial ID | Phase | Settings | Tumour Types | Treatment Arms | Status               |
|--------|------|------------------|-------|----------|--------------|----------------|---------------------|
| M6223  | NCT04457778 | 1                | Advanced/metastatic | Solid tumours | M6223 ± bintrafus alfa (M7924, bispecific TGF-β and PD-L1 Ab) | Recruiting         |
| TIM-3  | NCT03489343 | 1                | Advanced/metastatic | Solid tumours or lymphomas | Sym023 | Completed         |
| LY3321367 | NCT03099109 | 1                | Advanced/metastatic | Solid tumours | LY3300054 (anti-PD-L1) + LY321367 | Active, not recruiting |
|         | NCT02791334 | 1                | Advanced/metastatic | Solid tumours | LY3300054 (anti-PD-L1) ± LY321367 or abemaciclib or ramucirumab or merestinib | Active, not recruiting |
| Cobolimab (TSR-022) | NCT02817633 | 1                | Advanced/metastatic | Solid tumours | Cobolimab ± nivolumab or TSR-042 (anti-PD-1) ± TSR-033 or chemotherapy | Recruiting         |
|         | NCT03307785 | 1                | Advanced/metastatic | Solid tumours | Dostarlimab (TSR-042, anti-PD-1) ± TSR-022 + chemotherapy | Active, not recruiting |
|         | NCT04139902 | 2                | Ncoadjuvant       | Melanoma     | Cobolimab ± dostarlimab (TSR-042, anti-PD-1) | Recruiting         |
| Sabatolimab (MBG453) | NCT02608268 | 1, 2            | Advanced/metastatic | Solid tumours | Sabatolimab ± PDR001 vs. chemotherapy | Active, not recruiting |
| INCAGN02390 | NCT03652077 | 1                | Advanced/metastatic | Solid tumours | INCAGN02390 | Completed         |
| BMS-986258 | NCT03446040 | 1, 2            | Advanced/metastatic | Solid tumours | BMS-986258 + nivolumab or rHuPH20 | Active, not recruiting |
| SHR-1702 | NCT03871855 | 1                | Advanced/metastatic | Solid tumours | SHR-1702 ± camrelizumab (anti-PD-1) | Unknown            |
| RO7121661 | NCT03708328 | 1                | Advanced/metastatic | Solid tumours | RO7121661 | Active, not recruiting |
| B7-H3  | Enoblituzumab (MGA271) | NCT01391143 | 1            | Advanced/metastatic | Solid tumours | Enoblituzumab (MGA271) | Completed         |
|         | NCT02381314 | 1                | Advanced/metastatic | Solid tumours | Enoblituzumab + ipilimumab | Completed         |
|         | NCT02475213 | 1                | Advanced/metastatic | Solid tumours | Enoblituzumab + pembrolizumab or retifanlimab (MGA012, anti-PD-1) | Completed         |
| DS-7300a | NCT04145622 | 1, 2            | Advanced/metastatic | Solid tumours | DS-7300a | Recruiting         |
| Orlotamab (MGD009) | NCT02628535 | 1                | Advanced/metastatic | Solid tumours | Orlotamab (MGD009) | Terminated         |
|         | NCT03406949 | 1                | Advanced/metastatic | Solid tumours | Orlotamab + retifanlimab (MGA012, anti-PD-1) | Completed         |
| 4SCAR-276 | NCT04432649 | 1                | Advanced/metastatic | Solid tumours | 4SCAR-276 | Recruiting         |
| VISTA  | NCT02671955 | 1                | Advanced/metastatic | Solid tumours | JNJ-61610588 | Terminated         |
| CI-8993 | NCT04475523 | 1                | Advanced/metastatic | Solid tumours | CI-8993 | Recruiting         |
| CA-170  | NCT02812875 | 1                | Advanced/metastatic | Solid tumours or lymphomas | CA-170 | Completed         |
| ICOS   | Feladilimab | NCT03693612 | 2            | Advanced/metastatic | Solid tumours | Feladilimab + tremelimumab (anti-CTLA-4) vs. chemotherapy | Completed         |
| JTX-2011 | NCT02904226 | 1, 2            | Advanced/metastatic | Solid tumours | JTX-2011 ± pembrolizumab or nivolumab or ipilimumab | Completed         |
| KY1044  | NCT03829501 | 1, 2            | Advanced/metastatic | Solid tumours | KY1044 ± atezolizumab | Recruiting         |
The genotypic and phenotypic variability posed by inter- and intra-tumoral heterogeneity has shown promising potential in biological research, but several challenges remain in its integration into personalised drug design and clinical decision making. Firstly, a single tumour biopsy is a static and partial representation of the overall heterogeneity in a patient. Temporal analyses of multiple biopsies throughout the course of disease and treatment are required for the accurate depiction of spatial and temporal heterogeneity. Till date, repeated biopsies during and after treatment for disease progression have been incorporated into clinical trials [97,98]. Furthermore, the detection of tumour mutations in circulating tumour DNA has demonstrated feasibility and predictive values, which may be adapted as early diagnostic or relapse monitoring tools [99]. More research studies using non-targeted single-cell sequencing methods are also required to expand the understanding of rare patterns of heterogeneity and therapy resistance, and to guide novel drug development. Large scale collaborative efforts such as the Human Tumour Atlas Network [100] and the Human BioMolecular Atlas Program [101] are working towards combined databases of highly-multiplexed tissue imaging and single-cell omics data, to offer comprehensive cellular information in the context of cancer. The integration of spatial, single-cell and phenotypic datasets will empower a deeper understanding of heterogeneity at genomic, transcriptomic, proteomic and spatial organisation levels.

6. Conclusions

Heterogeneity of the tumour and microenvironment complexity are the main contributors to different treatment responses and clinical outcomes. The single-cell approach has contributed to the study of tumour heterogeneity and drug resistance arising from the TME. The advancement in single cell and spatial multi-omics platforms, as well as the integrated analysis of these large-scale datasets, are offering unprecedented powers to identify the intrinsic, extrinsic and interactive processes driving the development of tumour heterogeneity. The identification of the key and rare subpopulations of cells and molecular processes will aid in improving diagnosis and novel drug development for cancer patients.

Author Contributions: Conceptualisation, C.Q.; writing—original draft preparation, C.Q. and X.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: C.Q. is supported by CINSW Fellowship. X.B. is supported by the Australian Government Research Training Program Scholarship.

Conflicts of Interest: The authors declare no conflict of interest.
27. Durante, M.A.; Rodriguez, D.A.; Kurtenbach, S.; Kuznetsov, J.N.; Sanchez, M.I.; Decatur, C.L.; Snyder, H.; Feun, L.G.; Livingstone, A.S.; Harbour, J.W. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat. Commun. 2020, 11, 496. [CrossRef]
28. Nowell, P.C. The clonal evolution of tumor cell populations. Science 1976, 194, 23–28. [CrossRef]
29. Juntila, M.R.; de Sauvage, F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501, 346–354. [CrossRef]
30. McGranahan, N.; Favero, F.; de Bruin, E.C.; Birkbak, N.J.; Szallasi, Z.; Swanton, C. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 2015, 7, 283ra54. [CrossRef]
31. McGranahan, N.; Swanton, C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 2017, 168, 613–628. [CrossRef] [PubMed]
32. Grzywa, T.M.; Paskal, W.; Wlodarski, P.K. Intratumor and Intertumor Heterogeneity in Melanoma. Transl. Oncol. 2017, 10, 956–975. [CrossRef] [PubMed]
33. Jia, Q.Z.; Wang, A.; Yuan, Y.; Zhu, B.; Long, H. Heterogeneity of the tumor immune microenvironment and its clinical relevance. Exp. Hematol. Oncol. 2022, 11, 1–14. [CrossRef] [PubMed]
34. Tirosh, I.; Izar, B.; Prakadan, S.M.; Wadsworth, M.H., II; Treacy, D.; Trombetta, J.J.; Rotem, A.; Rodman, C.; Lian, C.; Murphy, G.; et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 2016, 352, 189–196. [CrossRef] [PubMed]
35. Noguchi, K.; Dalton, A.C.; Howley, B.V.; McCall, B.; Yoshida, A.; Diehl, J.A.; Howe, P.H. Interleukin-1-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines. PLoS ONE 2017, 12, e0177830. [CrossRef]
36. Müller, J.; Kriegsman, O.; Tsoi, J.; Robert, L.; Hugo, W.; Song, C.; Kong, X.; Possik, P.A.; Cornelissen-Steijger, P.D.; Foppen, M.H.G.; et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat. Commun. 2014, 5, 5712. [CrossRef]
37. Simmons, J.L.; Pierce, C.J.; Al-Ejeh, F.; Boyle, G.M. MITF and BRN2 contribute to metastatic growth after dissemination of melanoma. Sci. Rep. 2017, 7, 10909. [CrossRef]
38. Wolf, Y.; Bartok, O.; Patkár, S.; Eli, G.B.; Cohen, S.; Litchfield, K.; Levy, R.; Jiménez-Sánchez, A.; Trabish, S.; Lee, J.S.; et al. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. Cell 2019, 179, 219–235. [CrossRef]
39. Puram, S.V.; Tirosh, I.; Parikh, A.S.; Patel, A.P.; Yizhak, K.; Gillespie, S.; Rodman, C.; Luo, C.L.; Mroz, E.A.; Emerick, K.S.; et al. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. Cell 2017, 171, 1611–1624. [CrossRef]
40. Hugo, W.; Zaretsky, J.M.; Sun, L.; Song, C.; Moreno, B.H.; Hu-Lieskovsk, S.; Berent-Maoz, B.; Pang, J.; Chmielowski, B.; Cherry, G.; et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 2017, 168, 542. [CrossRef]
41. Kleppe, M.; Levine, R.L. Tumor heterogeneity confounds and illuminates: Assessing the implications. Nat. Med. 2014, 20, 342–344. [CrossRef]
42. Rodriguez-Meira, A.; Buck, G.; Clark, S.-A.; Povinelli, B.J.; Alcolea, V.; Louka, E.; McGowan, S.; Hamblin, A.; Sousos, N.; Barkas, N.; et al. Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing. Mol. Cell 2019, 73, 1292–1305.e8. [CrossRef]
43. Jerby-Arnov, L.; Shah, P.; Cuoco, M.S.; Rodman, C.; Su, M-J.; Melms, J.C.; Leeson, R.; Kanodia, A.; Mei, S.; Lin, J.-R.; et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell 2018, 175, 984–997.e24. [CrossRef]
44. Jamal-Hanjani, M.; Wilson, G.A.; McGranahan, N.; Birkbak, N.J.; Qi, Y.; Wang, C.; Kageyama, A.; Trabish, S.; Lee, J.S.; et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. eLife 2018, 7, 542. [CrossRef]
45. Yost, K.E.; Satpathy, A.T.; Wells, D.K.; Qi, Y.; Wang, C.; Kageyama, R.; McNamara, K.L.; Granja, J.M.; Sarin, K.Y.; Brown, R.A.; et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 2019, 25, 1251–1259. [CrossRef]
46. Fridman, W.H.; Pages, F.; Sautes-Fridman, C.; Galon, J. The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer 2012, 12, 298–306. [CrossRef]
47. Gejman, R.S.; Chang, A.Y.; Jones, H.F.; DiKun, K.; Hakimi, A.A.; Schietinger, A.; Scheinberg, D.A. Rejection of immunogenic tumor clones is limited by clonal fraction. elife 2018, 7, e41090. [CrossRef]
48. Riaz, N.; Havel, J.J.; Makarov, V.; Desrichard, A.; Urba, W.J.; Sims, J.S.; Hodi, F.S.; Martin-Algarra, S.; Mandal, R.; Sharman, W.H.; et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell 2017, 171, 934–949.e16. [CrossRef]
53. Fusi, A.; Berdel, R.; Havemann, S.; Nonnenmacher, A.; Keilholz, U. Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity. *Eur. J. Cancer* 2011, 47, 1971–1976. [CrossRef]

54. Bradish, J.R.; Richey, J.D.; Post, K.M.; Meehan, K.; Sen, J.D.; Malek, A.J.; Katona, T.M.; Warren, S.; Logan, T.F.; Fecher, L.A.; et al. Discordancy in BRAF mutations among primary and metastatic melanoma lesions: Clinical implications for targeted therapy. *Mol. Pathol.* 2015, 28, 480–486. [CrossRef]

55. Gide, T.N.; Quek, C.; Menzies, A.M.; Tasker, A.T.; Shang, P.; Holst, J.; Madore, J.; Lim, S.Y.; Velickovic, R.; Wongchenko, M.; et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/anti-CTLA-4 Combined Therapy. *Cancer Cell* 2019, 35, 238–255.e6. [CrossRef]

56. Su, Y.; Wei, W.; Robert, L.; Xue, M.; Tsoi, J.; Garcia-Diaz, A.; Moreno, B.H.; Kim, J.; Ng, R.H.; Lee, J.W.; et al. Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance. *Proc. Natl. Acad. Sci. USA* 2017, 114, 13679–13684.

57. Gremel, G.; Lee, R.J.; Girotti, M.R.; Mandal, A.K.; Valpione, S.; Garner, G.; Ayub, M.; Wood, S.; Rothwell, D.; Fusi, A.; et al. Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA. *Ann. Oncol.* 2016, 27, 1959–1965. [CrossRef]

58. Gide, T.N.; Pires da Silva, I.; Quek, C.; Ferguson, P.M.; Batten, M.; Shang, P.; Ahmed, T.; Menzies, A.M.; Carlin, M.S.; Saw, R.P.M.; et al. Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. *Cancers* 2021, 13, 3186. [CrossRef]

59. Gide, T.N.; Wilmott, J.S.; Scowler, R.A.; Long, G.V. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. *Clin. Cancer Res.* 2018, 24, 1260–1270. [CrossRef]

60. Sharma, P.; Hu-Lieskovsan, S.; Wargo, J.A.; Ribas, A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. *Cell* 2017, 168, 707–723. [CrossRef]

61. Kakavand, H.; Wilmott, J.S.; Menzies, A.M.; Vilain, R.; Haydu, L.E.; Yearley, J.H.; Thompson, J.F.; Kefford, R.F.; Hersey, P.; Long, G.V.; et al. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. *Clin. Cancer Res.* 2015, 21, 3140–3148. [CrossRef]

62. Goswami, S.; Tarapore, R.S.; Poenitzsch Strong, A.M.; TeSlaa, J.J.; Grinblat, Y.; Setaluri, V.; Spiegelman, V.S. MicroRNA-340-mediated degradation of microphthalmia-associated transcription factor (MITF) mRNA is inhibited by coding region determinant-binding protein (CRD-BP). *J. Biol. Chem.* 2015, 290, 389–395. [CrossRef]

63. Qian, H.; Yang, C.; Yang, Y. MicroRNA-26a inhibits the growth and invasiveness of malignant melanoma and directly targets on MITF gene. *Cell Death Discov.* 2017, 3, 17028. [CrossRef]

64. Hafildadottir, B.S.; Bergsteinsdottir, K.; Praetorius, C.; Steingrimsson, E. miR-148 regulates Mitf in melanoma cells. *PLoS ONE* 2010, 5, e11574. [CrossRef]

65. Ghafouri-Fard, S.; Gholidpour, M.; Taheri, M. MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets. *Front. Oncol.* 2021, 11, 608987. [CrossRef]

66. Kawakami, A.; Fisher, D.E. The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. *Lab. Invest.* 2017, 97, 649–656. [CrossRef]

67. Ho, Y.J.; Anaparthi, N.; Molik, D.; Mathew, G.; Aicher, T.; Patel, A.; Hicks, J.; Hammell, M.G. Single-cell RNA-seq analysis identifies markers of resistance to targeted BRAF inhibitors in melanoma cell populations. *Genome Res.* 2018, 28, 1353–1363. [CrossRef]

68. Estrela, J.M.; Salvador, R.; Marchio, P.; Valles, S.L.; López-Blanch, R.; Rivera, P.; Benlloch, M.; Alcácer, J.; Pérez, C.L.; Pellicer, J.A.; et al. Glucocorticoid receptor antagonism overcomes resistance to BRAF inhibition in BRAF(V600E)-mutated metastatic melanoma. *Am. J. Cancer Res.* 2019, 9, 2580–2598.

69. Lee, E.F.; Harris, T.J.; Tran, S.; Evangelista, M.; Arulananda, S.; John, T.; Rammac, C.; Hobbs, C.; Zhu, H.; Gunasigh, G.; et al. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. *Cell Death Discov.* 2019, 5, 17028. [CrossRef]

70. Lee, E.F.; Harris, T.J.; Tran, S.; Evangelista, M.; Arulananda, S.; John, T.; Rammac, C.; Hobbs, C.; Zhu, H.; Gunasigh, G.; et al. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. *Cell Death Discov.* 2019, 5, 17028. [CrossRef]

71. Liu, D.; Wang, S.; Bindeman, W. Clinical applications of PD-L1 bioassays for cancer immunotherapy. *J. Hematol. Oncol.* 2017, 10, 110. [CrossRef]

72. Long, G.; Larkin, J.; Ascierto, P.; Hodi, F.; Rutkowski, P.; Sileni, V.; Hassel, J.; Lebbe, C.; Pavlick, A.; Wagstaff, J. PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis. *Ann. Oncol.* 2016, 27, vi381. [CrossRef]

73. Madore, J.; Vilain, R.E.; Menzies, A.M.; Kakavand, H.; Wilmott, J.S.; Hyman, J.; Yearley, J.H.; Kefford, R.F.; Thompson, J.F.; Long, G.V.; et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/anti-PD-L1 clinical trials. *Pigment. Cell Melanoma Res.* 2015, 28, 245–253. [CrossRef] [PubMed]

74. Carlino, M.S.; Long, G.V.; Schadendorf, D.; Robert, C.; Ribas, A.; Richtig, E.; Nyakas, M.; Caglevic, C.; Tarhini, A.; Blank, C.; et al. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. *Eur. J. Cancer* 2018, 101, 236–243. [CrossRef] [PubMed]

75. Larkin, J.; Chiarioti-Sileni, V.; Gonzalez, R.; Grob, J.J.; Rutkowski, P.; Lao, C.D.; Cowey, C.L.; Schadendorf, D.; Wagstaff, J.; Dunner, R.; et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *N. Engl. J. Med.* 2019, 381, 1535–1546. [CrossRef] [PubMed]
76. Wolchok, J.D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Wagstaff, J.; Schadendorf, D.; Ferrucci, P.F.; et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *N. Engl. J. Med.* 2017, 377, 1343–1356. [CrossRef]
77. Shin, D.S.; Zaretsky, J.M.; Escuin-Ordinas, H.; Garcia-Diaz, A.; Hu-Lieskovan, S.; Kalbasi, A.; Grasso, C.S.; Hugo, W.; Sandooval, S.; Torrejon, D.Y.; et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. *Cancer Discov.* 2017, 7, 188–201. [CrossRef]
78. Zhou, J.; Gong, Z.; Jia, Q.; Wu, Y.; Yang, Z.-Z.; Zhu, B. Programmed death ligand 1 expression and CD8+ tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer. *Biochem. Biophys. Res. Commun.* 2018, 498, 751–757. [CrossRef]
79. Lee, J.H.; Shklovskaya, E.; Lim, S.Y.; Carlino, M.S.; Menzies, A.M.; Stewart, A.; Pedersen, B.; Irvine, M.; Alavi, S.; Yang, J.Y.H.; et al. Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition. *Nat. Commun.* 2020, 11, 1897. [CrossRef]
80. Russo, M.; Siravegna, G.; Blaszkowsky, L.S.; Corti, G.; Crisafulli, G.; Ahronian, L.G.; Mussolin, B.; Kwak, E.L.; Buscarino, M.; Lazzari, L.; et al. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. *Cancer Discov.* 2016, 6, 147–153. [CrossRef]
81. Hauschild, A.; Grob, J.-J.; Demidov, L.V.; Jouary, T.; Gutmer, R.; Millward, M.; Rutkowski, P.; Blank, C.U.; Miller, W.H., Jr.; Kaempgen, E. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 2012, 380, 358–365. [CrossRef]
82. Chapman, P.B.; Hauschild, A.; Robert, C.; Larkin, J.; Haanen, J.B.; Ribas, A.; Hogg, D.; Hamid, O.; Ascierto, P.A.; Testori, A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *N. Engl. J. Med.* 2014, 371, 1867–1876. [CrossRef]
83. Vidotto, T.; Saggioro, F.P.; Jamaspishvili, T.; Chesca, D.L.; Picanço de Albuquerque, C.G.; Reis, R.B.; Graham, C.H.; Berman, D.M.; Siemens, D.R.; Squire, J.A.; et al. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. *Cancer Discov.* 2018, 8, 1345–1356. [CrossRef] [PubMed]
84. Larkin, J.; Ascierto, P.A.; Dréno, B.; Atkinson, V.; Liszkay, G.; Maio, M.; Mandalà, M.; Demidov, L.; Stroyakovskiy, D.; Thomas, L. Pembrolizumab plus chemotherapy in advanced melanoma: A multicentre, open-label, phase 3 randomised controlled trial. *Lancet Oncol.* 2018, 19, 751–757. [CrossRef] [PubMed]
85. Motzer, R.J.; Tannir, N.M.; McDermott, D.F.; Frontera, O.A.; Melichar, B.; Choueiri, T.K.; Pimplak, E.R.; Barthélémy, P.; Porta, C.; George, S. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *N. Engl. J. Med.* 2018, 378, 1277–1290. [CrossRef]
86. Atkins, M.B.; Larkin, J. Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. *JNCI J. Natl. Cancer Inst.* 2016, 108, djv414. [CrossRef]
97. Lovly, C.M.; Salama, A.K.S.; Salgia, R. Tumor Heterogeneity and Therapeutic Resistance. *Am. Soc. Clin. Oncol. Educ. Book* **2016**, *35*, e585–e593. [CrossRef]

98. Reijers, I.L.M.; Menzies, A.M.; van Akkooi, A.C.J.; Versluis, J.M.; van den Heuvel, N.M.J.; Saw, R.P.M.; Pennington, T.E.; Kapiteijn, E.; van der Veldt, A.A.M.; Suijkerbuijk, K.P.M.; et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: The PRADO trial. *Nat. Med.* **2022**, *28*, 1178–1188. [CrossRef]

99. Gracie, L.; Pan, Y.; Atenafu, E.G.; Ward, D.G.; Teng, M.; Pallan, L.; Stevens, N.M.; Khoja, L. Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis. *Eur. J. Cancer* **2021**, *158*, 191–207. [CrossRef]

100. Rozenblatt-Rosen, O.; Regev, A.; Oberdoerffer, P.; Nawy, T.; Hupalowska, A.; Rood, J.E.; Ashenberg, O.; Cerami, E.; Coffey, R.J.; Demir, E.; et al. The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. *Cell* **2020**, *181*, 236–249. [CrossRef]

101. Snyder, M.P.; Lin, S.; Posgai, A.; Atkinson, M.; Regev, A.; Rood, J.; Rozenblatt-Rosen, O.; Gaffney, L.; Hupalowska, A.; Satija, R.; et al. The human body at cellular resolution: The NIH Human Biomolecular Atlas Program. *Nature* **2019**, *574*, 187–192.